Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Feng Chen

Internal Medicine Pembroke Pines, FL Medical Doctor

NPI 1184607749 CMS profile 189249

601 N Flamingo Rd Ste 104, Pembroke Pines, FL 33028

Open in the dashboard

General payments

$3,814

282 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Feng Chen of Pembroke Pines, FL is reported in the CMS Open Payments database as having received $3,814 across 282 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $212 9
2024 General $205 10
2023 General $792 33
2022 General $184 9
2021 General $390 25
2020 General $517 41
2019 General $1,513 155

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Feng Chen
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Feng Chen were reported at $212. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Feng Chen Internal Medicine median Middle half National median
2019 $1,513 $159 $48–$570 $163
2020 $517 $119 $33–$402 $114
2021 $390 $135 $37–$521 $132
2022 $184 $141 $42–$496 $149
2023 $792 $149 $45–$519 $160
2024 $205 $154 $47–$537 $164
2025 $212 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,201 91 payments
  2. AstraZeneca Pharmaceuticals LP $501 19 payments
  3. Lilly USA, LLC $301 22 payments
  4. Pfizer Inc. $272 25 payments
  5. Amarin Pharma Inc. $264 30 payments
  6. GlaxoSmithKline, LLC. $211 17 payments
  7. Merck Sharp & Dohme Corporation $207 29 payments
  8. Novartis Pharmaceuticals Corporation $173 7 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $151 9 payments
  10. Amgen Inc. $145 10 payments
  11. Other $391 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,756 274 payments
  2. Education $59 8 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,062 79 payments
  2. RYBELSUS $677 42 payments
  3. FARXIGA $311 13 payments
  4. JARDIANCE Diabetes $171 11 payments
  5. BREZTRI $142 4 payments
  6. Vascepa Hypertriglyceridemia $138 22 payments
  7. JARDIANCE Diabetes $132 8 payments
  8. ENTRESTO $130 5 payments
  9. STEGLUJAN $127 21 payments
  10. Vascepa Cardiovascular $126 8 payments
  11. Other $2,482 211 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 89 drugs

Part D claims

6,053

Median for Internal Medicine: 777

Drug cost

$642,107

Median for Internal Medicine: $73,373

Branded share of claims

23.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 134 $177,914
Jardiance Empagliflozin Brand 64 $87,359
Eliquis Apixaban Brand 75 $80,849
Rybelsus Semaglutide Brand 52 $74,880
Farxiga Dapagliflozin Propanediol Brand 24 $31,216
Tresiba Flextouch U-100 Insulin Degludec Brand 47 $23,208
Entresto Sacubitril/Valsartan Brand 16 $22,754
Xarelto Rivaroxaban Brand 28 $22,236
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $20,840
Janumet Sitagliptin Phos/Metformin Hcl Brand 12 $18,638

The 10 drugs with the highest cost, of 89 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$25,038

Medicare's payments for the services billed

Medicare patients

99

Average age 74

Services billed

457

50 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 46%
Arthritis 45%
Diabetes 44%
Ischemic heart disease 36%
COPD 23%
Depression 23%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $73
$73 52 —
Ozempic
  • Novo Nordisk Inc $73
$73 134 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $25
$25 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record